MedTrace Logo

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

NCT00648986 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-07-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether topical tazarotene (Tazorac), a receptor-selective synthetic retinoid that normalizes epidermal differentiation, ameliorates signs and symptoms of brittle nails.

Conditions

  • Brittle Nails

Interventions

DRUG

Tazorac

All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.

Sponsors & Collaborators

Principal Investigators

  • Richard Scher, MD · University of North Carolina

  • Julian Mackay-Wiggan, MD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00648986 on ClinicalTrials.gov